Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben, S.T., Heffron, T.P., Sutherlin, D.P., Bhat, S.R., Castanedo, G.M., Chuckowree, I.S., Dotson, J., Folkes, A.J., Friedman, L.S., Lee, L., Lesnick, J., Lewis, C., Murray, J.M., Nonomiya, J., Olivero, A.G., Plise, E., Pang, J., Prior, W.W., Salphati, L., Rouge, L., Sampath, D., Tsui, V., Wan, N.C., Wang, S., Wiesmann, C., Wu, P., Zhu, B.Y.(2010) Bioorg Med Chem Lett 20: 6048-6051
- PubMed: 20822905
- DOI: https://doi.org/10.1016/j.bmcl.2010.08.067
- Primary Citation of Related Structures:
3NZS, 3NZU - PubMed Abstract:
Starting from HTS hit 1a, X-ray co-crystallization and molecular modeling were used to design potent and selective inhibitors of PI3-kinase. Bioavailablity in this series was improved through careful modulation of physicochemical properties. Compound 12 displayed in vivo knockdown of PI3K pharmacodynamic markers such as pAKT, pPRAS40, and pS6RP in a PC3 prostate cancer xenograft model.
Organizational Affiliation:
Discovery Chemistry, Genentech, Inc., South San Francisco, CA 94080, USA. stevents@gene.com